635 related articles for article (PubMed ID: 22172603)
1. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM
Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603
[TBL] [Abstract][Full Text] [Related]
2. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
3. PVP and surfactant combined carrier as an effective absorption enhancer of poorly soluble astilbin in vitro and in vivo.
He Y; Liu H; Xie Z; Liao Q; Lai X; Du Z
Drug Dev Ind Pharm; 2014 Feb; 40(2):237-43. PubMed ID: 23350723
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
5. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.
Yang H; Teng F; Wang P; Tian B; Lin X; Hu X; Zhang L; Zhang K; Zhang Y; Tang X
Int J Pharm; 2014 Dec; 477(1-2):88-95. PubMed ID: 25455766
[TBL] [Abstract][Full Text] [Related]
6. Supersaturated polymeric micelles for oral cyclosporine A delivery.
Yu H; Xia D; Zhu Q; Zhu C; Chen D; Gan Y
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1325-36. PubMed ID: 23954511
[TBL] [Abstract][Full Text] [Related]
7. Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole.
Taupitz T; Dressman JB; Buchanan CM; Klein S
Eur J Pharm Biopharm; 2013 Apr; 83(3):378-87. PubMed ID: 23201048
[TBL] [Abstract][Full Text] [Related]
8. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
9. Supersaturable solid self-microemulsifying drug delivery system: precipitation inhibition and bioavailability enhancement.
Quan G; Niu B; Singh V; Zhou Y; Wu CY; Pan X; Wu C
Int J Nanomedicine; 2017; 12():8801-8811. PubMed ID: 29263669
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.
Thiry J; Kok MG; Collard L; Frère A; Krier F; Fillet M; Evrard B
Eur J Pharm Sci; 2017 Mar; 99():1-8. PubMed ID: 27951411
[TBL] [Abstract][Full Text] [Related]
11. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
12. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
[TBL] [Abstract][Full Text] [Related]
13. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.
Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S
Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903
[TBL] [Abstract][Full Text] [Related]
14. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers.
Ingels F; Beck B; Oth M; Augustijns P
Int J Pharm; 2004 Apr; 274(1-2):221-32. PubMed ID: 15072798
[TBL] [Abstract][Full Text] [Related]
15. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
16. The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions.
Hughey JR; Keen JM; Miller DA; Kolter K; Langley N; McGinity JW
Eur J Pharm Sci; 2013 Mar; 48(4-5):758-66. PubMed ID: 23348153
[TBL] [Abstract][Full Text] [Related]
17. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant - Soluplus.
Zi P; Zhang C; Ju C; Su Z; Bao Y; Gao J; Sun J; Lu J; Zhang C
Eur J Pharm Sci; 2019 Jun; 134():233-245. PubMed ID: 31028820
[TBL] [Abstract][Full Text] [Related]
18. Design of fenofibrate microemulsion for improved bioavailability.
Hu L; Wu H; Niu F; Yan C; Yang X; Jia Y
Int J Pharm; 2011 Nov; 420(2):251-5. PubMed ID: 21907776
[TBL] [Abstract][Full Text] [Related]
19. Use of the Flory-Huggins theory to predict the solubility of nifedipine and sulfamethoxazole in the triblock, graft copolymer Soluplus.
Altamimi MA; Neau SH
Drug Dev Ind Pharm; 2016 Mar; 42(3):446-455. PubMed ID: 26266965
[TBL] [Abstract][Full Text] [Related]
20. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
